MedTech Dive January 31, 2022
Medical device companies ended 2021 on an “uninspiring” note, J.P. Morgan analysts said, as they brace for a slowdown in procedures driven by a surge in COVID-19 cases due to the omicron variant.
If medical device companies hoped for smooth sailing into 2022, the latest surge in COVID-19 cases has put yet another obstacle in their path. Most medtechs saw their stocks tumble as they forecasted another challenging year, while the broader S&P 500 was also down in the last week of January.
Even analysts with J.P. Morgan were less than enthusiastic about the fourth-quarter earnings reports so far, expecting a “long stretch of rather uninspiring updates.”
“The bigger focus has been the 2022 guide, and while we...
Today's Sponsors
Today's Sponsor